络活喜与洛汀新联合治疗原发性高血压的临床疗效观察

The Antihypertensive Clinical Effects of Norvasc and Benazepril in Patients with Primary Hypertension

目的:评价络活喜和洛汀新联合治疗原发性高血压的临床疗效。方法:对我所2005年1月-2008年6月门诊治疗的82例患者随机分为络活喜联合洛汀新治疗组(I组,n=42)和单用络活喜治疗组(M组,n=40)。比较两组治疗4周后药物的有效性及安全性。结果:在原发性高血压患者中I组比M组的血压进一步下降,差异有统计学意义(P<0.05)。I组总有效率90.4%,M组总有效率72.5%,差异具有统计学意义(P<0.05)。M组心绞痛3例,非致死性心肌梗死2例,I组无一例发生,4例出现咳嗽。结论:原发性高血压患者采用络活喜和洛汀新联合治疗有效率优于单用络活喜,安全性高,适合临床推广应用。

Objective：To evaluate the clinical application of Norvasc and Benazepril in patients with primary hypertension.Methods：Eighty-two primary hypertension patients in our department were randomly divided into two groups,Norvasc and Benazepril therapy group（I group,n=42）and Norvasc group（M group,n=40）.Compared the safety and effectiveness of drug after treatment four weeks.Results：According to occasional measurements,there have significant differences of blood pressure between I group and M group（P0.05）,the blood pressure of I group was lower than M group.The efficient of I group was 90.4%,while the M group was 72.5%,there have significant differences between them（P0.05）.Three cases appeared angina,two cases appeared nonfatal myocardial infarction in M group,no one in I group,but four cases appeared cough.Conclusion：The antihypertensive efficient of Norvasc and Benazepril group was perfect than Norvasc group in patients with primary hypertension.This method has high safety and suitable for clinical application.